Home » Stocks » AVIR

Atea Pharmaceuticals, Inc. (AVIR)

Stock Price: $55.39 USD 1.12 (2.06%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 4.46B
Revenue (ttm) n/a
Net Income (ttm) -22.27M
Shares Out 80.74M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $55.39
Previous Close $54.27
Change ($) 1.12
Change (%) 2.06%
Day's Open 53.93
Day's Range 51.99 - 55.77
Day's Volume 109,788
52-Week Range 26.36 - 57.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 11 hours ago

Atea has a major deal with Roche. Atea just IPO-ed, but it already has $4.4bn in market cap.

GlobeNewsWire - 6 days ago

Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications

Zacks Investment Research - 1 month ago

Atea Pharmaceuticals (AVIR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing ...

GlobeNewsWire - 1 month ago

BOSTON, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell ...

GlobeNewsWire - 2 months ago

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing ...

Seeking Alpha - 2 months ago

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...

Other stocks mentioned: ALGM, BDSX, GATO, GLTO, LESL, LU, MAX, ROOT, SQZ
GlobeNewsWire - 2 months ago

Experienced Financial Executive Brings Leadership and Public Company Expertise Experienced Financial Executive Brings Leadership and Public Company Expertise

GlobeNewsWire - 2 months ago

Full Exercise of the Underwriters' Overallotment Brings Additional $45 Million Full Exercise of the Underwriters' Overallotment Brings Additional $45 Million

Seeking Alpha - 2 months ago

Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed.

Other stocks mentioned: ACICU, DSACU, GLTO, LESL, LUXAU, MAX, ROOT
GlobeNewsWire - 2 months ago

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing ...

Seeking Alpha - 2 months ago

Atea Pharmaceuticals intends to raise $253 million in a U.S. IPO of its common stock. The firm is developing treatments for virus-borne diseases such as Covid-19 and Hepatitis C.

24/7 Wall Street - 2 months ago

Atea Pharma has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering.

Market Watch - 2 months ago

Atea Pharmaceuticals Inc., a clinical-stage biotech that specializes in anti-viral therapies, set terms for its initial public offering on Monday with plans to offer 11 million shares priced a...

About AVIR

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 30, 2020
CEO
Jean-Pierre Sommadossi
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
AVIR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AVIR stock is "Strong Buy." The 12-month stock price forecast is 47.00, which is a decrease of -15.15% from the latest price.

Price Target
$47.00
(-15.15% downside)
Analyst Consensus: Strong Buy